Pethidine (meperidine) is a unique member of the opioid family. In addition to its analgesic activity, it also has significant local anaesthetic activity. This property enables it to be used as the sole agent for spinal anaesthesia. We describe the successful use of intrathecal pethidine 1 mg/kg for an elective lower segment caesarean section in a patient presumed to be allergic to amide local anaesthetics. There were no significant adverse effects in either the mother or the newborn.
A 38-year-old woman (G 3 P 0 ) with a complicated medical and anaesthetic history presented for elective lower segment caesarean section (LSCS) for pelvic dysmorphic disorder. At 22 years of age she was diagnosed with Wolff-Parkinson-White syndrome. She had also been diagnosed with rheumatoid arthritis as a child, had previously suffered from gout and was gluten intolerant. She described an episode of awareness under anaesthesia at age three while undergoing a repair of a head laceration. At age ten, she underwent a tooth extraction under bupivacaine local anaesthesia and suffered localised swelling, sloughing of skin and some difficulty breathing. Localised swelling, bruising and necrosis occurred with the removal of a ganglion using bupivacaine six years later. The use of amethocaine for the removal of a chalazion, in the interim, resulted in no adverse effects. Subsequent anaesthesia for tonsillectomy (at age 29) and dilatation and curettage (at 36 years), were undertaken without complication using total intravenous anaesthesia.
No formal allergy testing had been conducted. We found evidence 1,2 suggesting that provocative challenge testing could be undertaken in pregnant women near term, under controlled circumstances, with access to resuscitation drugs and equipment, and the ability to perform emergency LSCS if required. However, there is concern that such testing may result in foetal compromise or foetal sensitisation 3 , so advice from our local tertiary referral allergy clinic was sought. Testing during pregnancy was not recommended and the patient was also unwilling to consent to testing at that time.
The patient had also experienced adverse reactions to penicillin (anaphylaxis), cephalosporins (rash), tramadol (cardiac dysrhythmias, chest pain, nausea), povidone-iodine (skin irritation) and bee stings (anaphylaxis). After her mother had two intensive care admissions for suxamethonium apnoea, the patient was tested and found to have low pseudocholinesterase levels. Both her paternal twin uncles suffered from malignant hyperthermia (MH), but no formal MH contracture testing had been undertaken by the patient, her parents or siblings, due to difficulties in obtaining testing at the time. Pelvic dysmorphic disorder had been diagnosed as an incidental finding during a routine pregnancy ultrasound. Prior to this event the patient had never received pethidine (meperidine).
On the day of surgery the patient was in good health and weighed 84 kg. She was a nonsmoker and nondrinker and there were no concerning predictors for difficult airway management. Amethocaine gel was applied topically to her hands (for intravenous [IV] cannulation) and to her lower back one hour preoperatively. She was pre-treated with ondansetron 8 mg IV to reduce itch and nausea from the intrathecal opioid. An intrathecal injection of preservative-free pethidine 90 mg plus dextrose 10% 1 ml was given via the L3/4 intervertebral space without complication. A Bromage score of 4 and a sensory block to ice to T2 was confirmed ten minutes later. The operation proceeded uneventfully and a live male infant was born, with Apgar scores of 9 and 10 at one and five minutes, respectively.
During the procedure the patient had no nausea but frequently felt light-headed. She had no evidence of sedation or decreased respiratory rate or heart rate. Her blood pressure was maintained at an average systolic of 105 mmHg with metaraminol 5.5 mg in 0.5 mg aliquots. She was given lincomycin as antibiotic prophylaxis and paracetamol 1 g IV and indomethacin 100 mg per rectum.
In the post anaesthesia care unit (PACu), the patient received three further doses of metaraminol 0.5 mg. Three litres of IV fluid was given while she was in theatre and the PACU. No further IV fluid was ordered except to keep the vein open. Ninety minutes after the initial intrathecal dose, the sensory block had regressed to T6, and to T12 after a further hour. Full movement and sensation were regained after seven hours. IV morphine patient-controlled analgesia (PCA) was made available to the patient immediately postoperatively and was first used four hours after intrathecal pethidine; 30 mg was delivered across 18 hours, supplemented by regular oral paracetamol and ibuprofen. At six hours postintrathecal injection, an episode of nausea was relieved by a further dose of ondansetron.
At review 24 hours postpartum, the patient had no problems, including no signs of neurological deficit, and she was discharged home on day four. The patient was followed up at six, 12 and 18 months postpartum and had experienced no neurological symptoms.
DISCuSSION
This patient presented an anaesthetic challenge because of her numerous medical conditions. Due to the pelvic dysmorphic disorder she had declined vaginal delivery. A presumed allergy to amide local anaesthetic agents prevented use of these drugs, which are frequently used for spinal anaesthesia. Ester local anaesthetics were used in a topical form, having been used previously in this manner without adverse sequelae. Tetracaine has been used for spinal anaesthesia for LSCS 4 but was not available in a formulation suitable for intrathecal injection. The patient's family history of suxamethonium apnoea and malignant hyperthermia had implications for general anaesthesia and, as a result of her own research, the patient had requested spinal anaesthesia using intrathecal pethidine.
Pethidine is a phenylpiperidine derivative with agonist activity at mu and kappa opioid receptors 5 . It blocks sodium channels in a similar way to local anaesthetics, although with less overall potency than lignocaine 6 . It also shares structural features with atropine, but does not appear to have significant anticholinergic actions 5 . When administered intrathecally as a single dose, the most common side-effects are nausea and vomiting, hypotension, bradycardia, respiratory depression and pruritus 7 .
Pethidine has been known to have local anaesthetic properties since the 1940s but its use as a sole agent for spinal anaesthesia was not reported until 1982 7 . Since then, numerous other reports of intrathecal pethidine have followed for general [8] [9] [10] , urological 11, 12 and orthopaedic surgery 13, 14 , as an adjunct to intrathecal local anaesthetic for labour and caesarean section [15] [16] [17] and as a sole drug for labour 18, 19 or caesarean section 4, [20] [21] [22] [23] [24] .
The reported dose of intrathecal pethidine for LSCS has been either 1 mg/kg 4, [20] [21] [22] [23] [24] or a fixed dose of 50 mg 22 . In three cases, 10% dextrose was added 4, 22, 23 . Pethidine has hyperbaric properties when injected intrathecally 7 but the onset time can be up to 20 minutes 21 . In cases where the patient was placed supine immediately after the intrathecal injection, a relatively high block has been described. Keeping patients sitting has been used to minimise the cephalad spread of block for urological procedures 7 .
We used a dose of 1 mg/kg in keeping with the majority of published studies and dextrose was added to create a hyperbaric solution, allowing greater control of the level of the block. In our patient, the block did not ascend above T2 as tested with ice and this proved sufficient throughout the surgery.
Intrathecal pethidine has been associated with a number of side-effects. In the obstetric population both hypotension 4,21-23 and no significant change in blood pressure, compared to local anaesthetic, has been reported 20, 24 . Our patient experienced a period of hypotension, which started approximately five minutes after injection and lasted for about 35 minutes. During this time the blood pressure varied between a minimum systolic of 85 mmHg and a maximum of 118 mmHg and was supported by a substantial dose of metaraminol. More doses of metaraminol were required in the PACu, until two hours after the injection of pethidine, but hypotension was not recorded thereafter. While bradycardia 11 and respiratory depression 9 have been reported in non-obstetric patients, they have not been noted in patients undergoing LSCS, nor did they occur in our patient. Nausea, vomiting and pruritus are common side-effects 4, 21, 22, 24 . In one study and one case report, metoclopramide 10 mg was given successfully for prophylaxis 20, 23 . We used ondansetron 8 mg IV approximately 30 minutes before the onset of the block and the patient had no nausea until six hours later, after the commencement of PCA, which is associated with a high incidence of nausea and vomiting.
Case RePoRT
Anaesthesia and Intensive Care, Vol. 41, No. 1, January 2013 Due to dual local anaesthetic and opioid agonist properties, a potential advantage of intrathecal pethidine compared with local anaesthetic is a longer period of postoperative analgesia 7 . Studies using pethidine as a sole agent reported a duration of four to eight hours before further analgesia was required 4, [20] [21] [22] 24 . Our patient commenced PCA four hours after the onset of the block, at which time her maximum pain score on a verbal numerical scale was two. Her subsequent 24-hour morphine consumption was low.
In summary, this patient presented a number of challenges because of her allergies and familial risk factors. The unique characteristics of pethidine, which made it suitable as a sole drug for spinal anaesthesia, allowed this patient to have her operative delivery under regional anaesthesia. She had minimal sideeffects and these were easily managed. While intrathecal pethidine may be more frequently used in developing countries due to its low-cost and the limited availability of local anaesthetics 7 , its use in developed countries as a systemic agent has declined because of its side-effect profile and addictive potential 5,25 , as well as guidelines which discourage its use 26 . Despite this, it is useful in specific clinical situations and presumed amide local anaesthetic allergy is one such situation.
